DiaphOne Therapeutics
PrivateLast Round
Pre Seed
Oct 1, 2024
Company Overview
DiaphOne Therapeutics is a biotechnology company developing first-in-class small molecule RAGE antagonists for diabetic nephropathy, neurodegeneration, and other indications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DiaphOne Therapeutics Comps
Public and private peers based on sector, stage, and business model.
DiaphOne Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Oct 1, 2024 |
DiaphOne Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NLC Health Impact Fund | Pre Seed |
| NLC Health Ventures | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2024
Led by NLC Health Ventures and NLC Health Impact Fund.
DiaphOne Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about DiaphOne Therapeutics's valuation, stock price, and market status.
